Tekla Capital Management’s Celldex Therapeutics CLDX Stock Holding History

Tekla Capital Management’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-7,053	Closed	-$236K	–	178
2021 Q2	$236K	Hold	7,053	–	–	0.01%	185
2021 Q1	$145K	Hold	7,053	–	–	0.01%	193
2020 Q4	$124K	Hold	7,053	–	–	﹤0.01%	198
2020 Q3	$105K	Hold	7,053	–	–	﹤0.01%	201
2020 Q2	$92K	Hold	7,053	–	–	﹤0.01%	220
2020 Q1	$12K	Hold	7,053	–	–	﹤0.01%	216
2019 Q4	$16K	Hold	7,053	–	–	﹤0.01%	214
2019 Q3	$15K	Hold	7,053	–	–	﹤0.01%	192
2019 Q2	$19K	Hold	7,053	–	–	﹤0.01%	197
2019 Q1	$35K	Hold	7,053	–	–	﹤0.01%	193
2018 Q4	$21K	Hold	7,053	–	–	﹤0.01%	203
2018 Q3	$48K	Hold	7,053	–	–	﹤0.01%	211
2018 Q2	$53K	Hold	7,053	–	–	﹤0.01%	180
2018 Q1	$247K	Hold	7,053	–	–	0.01%	183
2017 Q4	$300K	Hold	7,053	–	–	0.01%	158
2017 Q3	$303K	Hold	7,053	–	–	0.01%	149
2017 Q2	$261K	Hold	7,053	–	–	0.01%	141
2017 Q1	$382K	Hold	7,053	–	–	0.01%	135
2016 Q4	$375K	Hold	7,053	–	–	0.02%	139
2016 Q3	$427K	Hold	7,053	–	–	0.02%	139
2016 Q2	$464K	Hold	7,053	–	–	0.02%	152
2016 Q1	$400K	Hold	7,053	–	–	0.02%	136
2015 Q4	$1.66M	Sell	7,053 -15,507	-69%	-$3.38M	0.06%	124
2015 Q3	$3.57M	Buy	+22,560	New	+$6.39M	0.13%	117
2014 Q4	–	Sell	-33,893	Closed	-$6.59M	–	102
2014 Q3	$6.59M	Buy	+33,893	New	+$7.38M	0.31%	70

Other funds holding CLDX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Tekla Capital Management's CLDX Position: Q3 2021 in Review

Tekla Capital Management sold out of Celldex Therapeutics (CLDX) in Q3 2021, closing a stake of 7,053 shares — an estimated $236K sold.

Tekla Capital Management first reported a position in CLDX in Q3 2014 and held it in 25 quarters. The position peaked at $6.59M in Q3 2014. 160 funds tracked by Wall St. Rank hold CLDX as of Q3 2021.

Tekla Capital Management reported no remaining Celldex Therapeutics position as of Q3 2021 after selling out during the quarter.
Tekla Capital Management sold 7,053 Celldex Therapeutics shares in Q3 2021, an estimated $236K.
Tekla Capital Management first reported a position in Celldex Therapeutics in Q3 2014 and held it in 25 quarters.
Tekla Capital Management's Celldex Therapeutics position peaked at $6.59M in Q3 2014.
160 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2021.

Based on Tekla Capital Management's 13F filing for Q3 2021, filed 12 Nov 2021.